C4 Therapeutics, Inc. Stock Price, News & Analysis

C4 Therapeutics (NASDAQ:CCCC) has entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the combination of cemsidomide and elranatamab for treating relapsed/refractory multiple myeloma. The upcoming Phase 1b trial, set to begin in Q2 2026, will assess the safety and optimal dosing of cemsidomide (an IKZF1/3 degrader) with dexamethasone and elranatamab (Pfizer's BCMAxCD3 bispecific antibody) as a second-line or later therapy.

Under the agreement, Pfizer will provide elranatamab at no cost, while C4T will sponsor and conduct the trial. Early Phase 1 data shows cemsidomide demonstrates robust T-cell activation and cytokine expression, suggesting potential synergistic effects when combined with elranatamab to enhance anti-myeloma immune response.

C4 Therapeutics (NASDAQ:CCCC) presented promising Phase 1 clinical trial data for cemsidomide, an oral IKZF1/3 degrader, in combination with dexamethasone for treating relapsed/refractory multiple myeloma. The trial showed 50% overall response rate (ORR) at the highest dose level (100 µg) and 40% ORR at the 75 µg dose level in heavily pre-treated patients.

Key highlights include a median duration of response of 9.3 months across all dose levels, with median duration not yet reached at the two highest doses. The drug demonstrated a favorable safety profile with no treatment discontinuations and minimal dose reductions. The study involved 72 patients who had received a median of seven prior therapies, with 75% having previous BCMA-targeted therapy exposure.

C4T plans to pursue two distinct opportunities for accelerated approval through a Phase 2 trial in Q1 2026 for fourth-line therapy and a Phase 1b trial in Q2 2026 to evaluate combination with BCMA BiTE in second-line therapy.

C4 Therapeutics (NASDAQ: CCCC) announced that its collaboration partner Biogen received FDA acceptance of the IND application for BIIB142, an IRAK4 degrader targeting autoimmune diseases. This marks a significant milestone in their strategic collaboration initiated in 2018.

The partnership combines C4T's expertise in targeted protein degradation with Biogen's drug development capabilities. C4T has delivered two development candidates to Biogen, who will handle future clinical development and commercialization. C4T will receive a $2 million milestone payment when Biogen begins dosing patients in the BIIB142 clinical trial.

C4 Therapeutics (Nasdaq: CCCC) announced upcoming data presentation from its Phase 1 trial of cemsidomide in multiple myeloma at the International Myeloma Society Annual Meeting on September 20, 2025. The company has completed enrollment and dose escalation for the trial, which combines cemsidomide with dexamethasone.

The presentation will feature data from all safety and efficacy evaluable multiple myeloma patients across all dose levels. Initial results indicate a well-tolerated safety profile and compelling response rates. Dr. Binod Dhakal from the Medical College of Wisconsin will present the findings at 11:10 am ET in Toronto. C4T will host an investor webcast at 3 pm ET the same day to discuss the data and outline future clinical development plans.

C4 Therapeutics (NASDAQ:CCCC) reported Q2 2025 financial results and business updates, highlighting progress in its targeted protein degradation pipeline. The company's lead drug cemsidomide demonstrated promising Phase 1 results with 40% overall response rate (ORR) at 75 µg dose and 50% ORR at 100 µg dose in multiple myeloma patients.

Financial results showed revenue of $6.5M (down from $12.0M in Q2 2024), with a net loss of $26.0M. The company maintains a strong financial position with $223.0M in cash, extending runway to mid-2027. A milestone payment of $1M was earned from the Merck KGaA collaboration focused on KRAS family projects.

Following a productive FDA Type C meeting, C4T plans to initiate registrational development of cemsidomide in early 2026, focusing on multiple myeloma over non-Hodgkin's lymphoma for strategic reasons.

C4 Therapeutics (NASDAQ: CCCC) reported Q1 2025 financial results and key developments. The company's lead drug cemsidomide showed promising results in multiple myeloma treatment, achieving a 50% overall response rate at 100 µg dose and 40% ORR at 75 µg dose. Notably, one patient achieved minimal residual disease negative complete response. The company has completed Phase 1 dose escalation for multiple myeloma and expects FDA feedback by mid-2025. C4T reported $234.7 million in cash and equivalents, providing runway into 2027. Q1 2025 revenue was $7.2 million, up from $3.0 million in Q1 2024, while net loss decreased to $26.3 million ($0.37 per share) from $28.4 million. The company is prioritizing cemsidomide development while seeking partnership opportunities for its BRAF program.

C4 Therapeutics (CCCC) reported its Q4 and full year 2024 financial results, highlighting progress in its degrader portfolio. The company ended 2024 with $267.3 million in cash, providing runway into 2027.

Key clinical developments include cemsidomide showing a 36% overall response rate in Multiple Myeloma and 38% across NHL subtypes. In PTCL, cemsidomide achieved a 44% overall response rate. Clinical trials for both indications are expected to initiate in early 2026.

Financial highlights for 2024 include revenue of $35.6 million, up from $20.8 million in 2023. R&D expenses decreased to $110.6 million from $117.7 million, while G&A expenses remained flat at $42.1 million. Net loss improved to $105.3 million ($1.52 per share) compared to $132.5 million ($2.67 per share) in 2023.

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation science, has announced its participation in two major investor conferences in March 2025.

The company will present at the TD Cowen 45th Annual Healthcare Conference on March 3rd at 9:10 am ET in Boston, MA. A live webcast will be accessible through the company's website's Events & Presentations page, with replay available for approximately 30 days after the event.

Additionally, management will attend the Leerink Partners Global Healthcare Conference on March 9th in Miami, FL.

C4 Therapeutics (CCCC) announced its 2025 milestones for its clinical portfolio of degrader medicines in oncology. The company highlighted progress across three main programs: cemsidomide for multiple myeloma and non-Hodgkin's lymphoma, CFT1946 for BRAF V600X solid tumors, and CFT8919 for non-small cell lung cancer.

Key developments include cemsidomide's promising data presented at ASH, showing a 36% overall response rate in multiple myeloma and 38% in non-Hodgkin's lymphoma. CFT1946's Phase 1 monotherapy dose escalation is expected to complete in H1 2025, with data in melanoma and colorectal cancer expected in H2 2025. The company's cash runway is expected to fund operations into 2027.

The company plans to initiate new clinical studies for cemsidomide in early 2026, including combinations with other agents for multiple myeloma and monotherapy for peripheral T-cell lymphoma. Data from CFT8919's Phase 1 study in Greater China will inform future development plans.